{"id":3180,"date":"2014-04-23T06:30:00","date_gmt":"2014-04-23T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/interim-report-january-march-2014\/"},"modified":"2014-04-23T06:30:00","modified_gmt":"2014-04-23T06:30:00","slug":"interim-report-january-march-2014","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/","title":{"rendered":"Interim Report January – March 2014"},"content":{"rendered":"
CONTINUED STRONG SALES GROWTH AND REGULATORY SUCCESSES WITH XPS\u2122 AND STEEN SOLUTION\u2122<\/strong><\/div>\n<\/p>\n

FIRST QUARTER 2014 (JAN \u2013 MAR)<\/span><\/span><\/p>\n

\u2022 Net sales in the quarter amounted to SEK 18.3 (16.3) million, corresponding to an increase of 12 percent in SEK. Sales increased by 10 percent in local currency.<\/span><\/span><\/p>\n

\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.1 (3.8) million, corresponding to an EBITDA margin of 17 percent.<\/span><\/span><\/p>\n

\u2022 Net income amounted to SEK 1.8 (2.4) million, resulting in earnings per share of SEK 0.09 (0.12). <\/span><\/span><\/p>\n

\u2022 Cash flow from operating activities was SEK -3.3 (4.0) million due to changes in trade payables that amounted to SEK -3.6 million and paid taxes that amounted to SEK -2.6 million.<\/span><\/span><\/p>\n

\u2022 STEEN Solution\u2122 and related products accounted for 24 (16) percent of total sales.<\/span><\/span><\/p>\n

\u2022 The Advisory Panel convened by the FDA voted unanimously, by 10 votes to 0, that the XPS\u2122 System with STEEN Solution\u2122 meets the requirements for HDE (Humanitarian Device Exemption) approval.<\/span><\/span><\/p>\n

\u2022 XPS\u2122 (Xvivo Perfusion System) received a CE mark, allowing XPS\u2122 and the accompanying single-use products to be sold in Europe.<\/span><\/span><\/p>\n

\u2022 The first lung transplant in Turkey using a lung treated with the STEEN Solution\u2122 method was performed at Sureyyapasa Teaching Hospital.<\/span><\/span><\/p>\n

\u2022 Barnes Jewish Hospital in St. Louis, which is a pioneer in lung transplantation, will be the tenth transplant center to participate in the NOVEL trial. Organ Procurement Organization* (OPO) Mid-America Transplant Services in Missouri has bought an XPS\u2122 to strengthen the collaboration between transplant centers and OPOs. The company plans to continue deploying XPS\u2122 with recovery of costs, at transplant centers in the United States during the second quarter.<\/span><\/span><\/p>\n<\/p>\n

CONFERENCE CALL<\/span><\/span><\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, April 23, 2014. Telephone: +46 8 50336434, enter code 1319928<\/span><\/span><\/p>\n<\/p>\n

April 23, 2014
<\/span> Gothenburg <\/span><\/p>\n

XVIVO Perfusion AB (publ)
<\/span> Magnus Nilsson, CEO<\/span><\/p>\n

** An OPO or Organ Procurement Organization is responsible for coordination and assessment of donated organs for organ transplantation in a region in the US.<\/span><\/span><\/p>\n

\n

For further information please contact:
<\/span>
Christoffer Rosenblad, CFO, +46 31\u00a0788 21 59, christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

XVIVO Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and\/or the Financial Instruments Trading Act. The information was submitted for publication on\u00a0April 23, 2014\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CONTINUED STRONG SALES GROWTH AND REGULATORY SUCCESSES WITH XPS\u2122 AND STEEN SOLUTION\u2122 FIRST QUARTER 2014 (JAN \u2013 MAR) \u2022 Net…<\/p>\n","protected":false},"template":"","class_list":["post-3180","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim-q1","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim"],"acf":[],"yoast_head":"\nInterim Report January - March 2014 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim Report January - March 2014 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"CONTINUED STRONG SALES GROWTH AND REGULATORY SUCCESSES WITH XPS\u2122 AND STEEN SOLUTION\u2122 FIRST QUARTER 2014 (JAN \u2013 MAR) \u2022 Net...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2014\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2014\\\/\",\"name\":\"Interim Report January - March 2014 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2014-04-23T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2014\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2014\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2014\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim Report January – March 2014\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim Report January - March 2014 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/","og_locale":"en_US","og_type":"article","og_title":"Interim Report January - March 2014 - XVIVO","og_description":"CONTINUED STRONG SALES GROWTH AND REGULATORY SUCCESSES WITH XPS\u2122 AND STEEN SOLUTION\u2122 FIRST QUARTER 2014 (JAN \u2013 MAR) \u2022 Net...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/","name":"Interim Report January - March 2014 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2014-04-23T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2014\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Interim Report January – March 2014"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}